<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998751</url>
  </required_header>
  <id_info>
    <org_study_id>AB04016</org_study_id>
    <nct_id>NCT00998751</nct_id>
  </id_info>
  <brief_title>Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)</brief_title>
  <official_title>Phase 2 Study of Oral AB1010 in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the
      treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST)</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>until disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Gastro-intestinal Stromal Tumours</condition>
  <arm_group>
    <arm_group_label>masitinib (AB1010)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral masitinib 7.5 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral masitinib</intervention_name>
    <description>7.5 mg/kg/day</description>
    <arm_group_label>masitinib (AB1010)</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female patients, age &gt;18

          -  Life expectancy &gt; 6 months

          -  Histological proven, metastatic, or locally advanced and non-operable, non-
             pre-treated GIST.

          -  Patients having never received any tyrosine kinase inhibitor, including as adjuvant
             therapy

          -  C-Kit (CD117) positive tumors detected immuno-histochemically

          -  Measurable tumor lesions with longest diameter &gt;20 mm using conventional techniques or
             &gt;10 mm with spiral CT scan

        Exclusion Criteria:

          -  Documented allergy to the similar drug of AB1010

          -  Inadequate organ function

          -  Patients with a history of any other malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lecesne</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.ejcancer.com/article/S0959-8049(10)00117-6/fulltext</url>
    <description>Publication of results</description>
  </link>
  <results_reference>
    <citation>Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer. 2010 May;46(8):1344-51. doi: 10.1016/j.ejca.2010.02.014. Epub 2010 Mar 6.</citation>
    <PMID>20211560</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 19, 2009</study_first_submitted>
  <study_first_submitted_qc>October 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2009</study_first_posted>
  <last_update_submitted>December 8, 2018</last_update_submitted>
  <last_update_submitted_qc>December 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cKIT inhibitor</keyword>
  <keyword>GIST</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

